Abstract

One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine.

HIV vaccine candidates often have limited capacity to induce broadly neutralizing antibodies (nAbs). In this study, the authors show that stabilized Clade C HIV-1 Env protein trimers decorated on CoPoP liposomes induce nAbs against 18 of 20 multiclade tier 2 HIV-1 strains in immunized rabbits.

Details

Title
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
Author
Koornneef, Annemart 1 ; Vanshylla, Kanika 1 ; Hardenberg, Gijs 1 ; Rutten, Lucy 1   VIAFID ORCID Logo  ; Strokappe, Nika M. 1   VIAFID ORCID Logo  ; Tolboom, Jeroen 1 ; Vreugdenhil, Jessica 1 ; Boer, Karin Feddes-de 1 ; Perkasa, Aditya 1 ; Blokland, Sven 1   VIAFID ORCID Logo  ; Burger, Judith A. 2 ; Huang, Wei-Chiao 3 ; Lovell, Jonathan F. 3 ; van Manen, Danielle 1 ; Sanders, Rogier W. 2   VIAFID ORCID Logo  ; Zahn, Roland C. 1   VIAFID ORCID Logo  ; Schuitemaker, Hanneke 1   VIAFID ORCID Logo  ; Langedijk, Johannes P. M. 4 ; Wegmann, Frank 1   VIAFID ORCID Logo 

 Janssen Vaccines & Prevention, Leiden, The Netherlands (GRID:grid.497529.4) (ISNI:0000 0004 0625 7026) 
 University of Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Medical Microbiology, Amsterdam UMC, Amsterdam, the Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262) 
 University at Buffalo, Department of Biomedical Engineering, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887) 
 Janssen Vaccines & Prevention, Leiden, The Netherlands (GRID:grid.497529.4) (ISNI:0000 0004 0625 7026); ForgeBio, Amsterdam, The Netherlands (GRID:grid.497529.4) 
Pages
3128
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3037198624
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.